Final-Program-ATS-2023-AP.vp

WEDNESDAY • MAY 24

313

9:24 The Effect of Pulmonary Vasodilator Therapy in Patients With Sarcoidosis-associated Pulmonary Hypertension/ S. Gayen, Philadelphia, PA 9:36 Changes in FDG-PET Scan Activity in Sarcoidosis and Pulmonary Function Studies/ G.W. Soo Hoo, Los Angeles, CA 9:48 Serum Ace Levels and RAAS Modulation on Mortality in Patients With Sarcoidosis/ J. Fares, Philadelphia, PA

9:36 Anti-C5a Vilobelimab Reduces All-cause Mortality in Critically Ill COVID-19 Patients and in Those With Severe ARDS: A Phase 3 Randomized Double-blind, Placebo-controlled Study/ M. Witzenrath, Berlin, Germany 9:48 Oxygen-saturation Targets for Adults Receiving

Mechanical Ventilation After Cardiac Arrest: A Secondary Analysis of the PILOT Trial/ K.P. Seitz, Nashville, TN

CLINICAL MINI SYMPOSIUM

BASIC • CLINICAL • TRANSLATIONAL MINI SYMPOSIUM

D16

ADVANCING THE SCIENCE OF ARDS AND ACUTE RESPIRATORY FAILURE

D17

BUGS, LUNGS, AND THE ENVIRONMENT: THE INTERPLAY BETWEEN AMBIENT EXPOSURES, MICROBIOME, AND RESPIRATORY INFECTION

8:00 a.m. - 10:00 a.m.

Walter E. Washington Convention Center Ballroom B (Level 3)

Chairing: C. O’Kane, MD, PhD, Belfast, United Kingdom R.G. Khemani, MD, MSCR, Los Angeles, CA N.J. Meyer, MD, MS, ATSF, Philadelphia, PA Oral Presentations: 8:00 A New Global Definition of Acute Respiratory Distress Syndrome/ M.A. Matthay, San Francisco, CA 8:12 Hemodynamic Variations Are Associated With Increased Odds of Discrepancy Between Pulse Oximeter and Arterial Oxygen Saturation/ R. Rovinski, Miami, FL 8:24 Endothelial Glycocalyx Degradation in Pediatric Acute Respiratory Distress Syndrome/ C.J. Sallee, Los Angeles, CA 8:36 Glycocalyx Degradation Products in Pulmonary Edema Fluid Are Higher in ARDS Than Cardiogenic Edema and Are Associated With Poor Outcomes and Decreased Compliance of the Respiratory System/ L. Yun, Nashville, TN 8:48 Patterns of Biomarker Dysregulation in Mortality Differ Between ARDS and Sepsis Phenotypes/ M. Maddali, Stanford, CA 9:00 The Hyperinflammatory and Hypoinflammatory Phenotypes Have Divergent Clinical Outcomes in Sepsis and Differential Response to Activated Protein C/ P. Sinha, St. Louis, MO 9:12 Plasma SARS-CoV-2 Nucleocapsid Antigen Levels Are Associated With In-hospital Mortality in Hospitalized Patients With COVID-19/ K. Sullivan, San Francisco, CA 9:24 Latent Class Analysis Identifies Novel Phenotypes of Severe COVID-19 Pneumonia/ N. Alipanah-Lechner, San Francisco, CA

8:00 a.m. - 10:00 a.m.

Walter E. Washington Convention Center Room 202 A (Level 2)

Chairing: L. Smit, PhD, Utrecht, Netherlands

D. Croft, MD, MPH, ATSF, Rochester, NY I. Jaspers, PhD, Chapel Hill, NC

Oral Presentations: 8:00 Gut Microbiome Transplant Confers Predisposition to Asthma Triggered by Prenatal Exposure to Environmental Particles, Requires Viable Bacteria/ A.V. Fedulov, Providence, RI 8:12 Infant Lower Respiratory Infections and the Premature Death of Adults From Respiratory Disease - a Seventy-three Year Longitudinal Nationally Representative Birth Cohort Study/ J. Allinson, London, United Kingdom 8:24 Rates and Risk Factors for RSV Infection Among Term Healthy Infants in a Population-based US Cohort/ F. Cacho, Nashville, TN 8:36 Organic Dust Exposure Enhances SARS-CoV-2 Entry in a PKC a - and ADAM-17-dependent Manner/ T.A. Wyatt, Omaha, NE 8:48 Risk of Cardiovascular Events Post-COVID-19 in People With Pre-existing Chronic Respiratory Diseases/ H. Whittaker, London, United Kingdom 9:00 The Effect of the COVID-19 Pandemic on Community Respiratory Virus Prevalence and Healthcare Utilization Related to Asthma, Chronic Obstructive Pulmonary Disease, and Respiratory Tract Infection/ T. Ho, Hamilton, Canada

ATS 2023 • Washington, DC